X-linked mental retardation: Further lumping, splitting and emerging phenotypes

Clinical Genetics

Volumn 67, Issue 6, 2005, Pages 451-467

  Kleefstra, T ^a   Hamel, Ben C J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

MRX; MRXS; Phenotypes; Review; XLMR

Indexed keywords

BINDING PROTEIN; GENE PRODUCT; HOMEODOMAIN PROTEIN; METHYL CPG BINDING PROTEIN 2;

AUTOSOMAL DOMINANT INHERITANCE; BRAIN FUNCTION; CLINICAL FEATURE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEX DIFFERENCE; SHORT SURVEY; X CHROMOSOMAL INHERITANCE; X LINKED MENTAL RETARDATION;

ADULT; CHROMOSOME MAPPING; GENES; GENOTYPE; HUMANS; MALE; MENTAL RETARDATION, X-LINKED; MUTATION; PHENOTYPE;

EID: 18344382916     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2005.00434.x     Document Type: Short Survey

References (135)

1. American Association on Mental Retardation. Mental Retardation: Definition, Classification, and Systems of Supports; 10th edn. Washington, 2002.
2. Hamel BCJ. X-linked mental retardation; a clinical and molecular study. PhD Thesis. Nijmegen (webdoc.ubn.-kun.nl/mono/h/hamel_b/xlinmere.pdf) 1999.
3. Leonard H, Wen X. The epidemiology of mental retardation: challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev 2002: 8: 117-134.
4. Turner G, Turner B. X-linked mental retardation. J Med Genet 1974: 11: 109-113.
5. Penrose LS. A clinical and genetic study on 1280 cases of mental defect. Special report series, Medical Research Council, London 1938.
6. Lehrke RG. A theory of X-linkage of major intellectual traits. Am J Ment Defic 1972: 76: 611.
7. Herbst DS, Miller JR. Nonspecific X-linked mental retardation II. the frequency in British Columbia. Am J Med Genet 1980: 7: 461-469.
8. Croen LA, Grether JK, Selvin S. The epidemiology of mental retardation of unknown cause. Pediatrics 2001: 107: E86.
9. Frints SG, Froyen G, Marynen P, Fryns JP. X-linked mental retardation. vanishing boundaries between non-specific (MRX) and syndromic (MRXS) forms. Clin Genet 2002: 62: 423-432.
10. Ropers HH, Hamel BCJ. X-linked mental retardation. Nat Rev Genet 2005: 6: 46-57.
11. Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001: 3: 359-371.
12. de Vries BBA, van den Ouweland AMW, Mohkamsing S et al. Collaborative Fragile X, Study Group. Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Am J Hum Genet 1997: 61: 660-667.
13. Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996: 64: 196-197.
14. Fishburn J, Turner G, Daniel A, Brookwell R. The diagnosis and frequency of X-linked conditions in a cohort of moderately retarded males with affected brothers. Am J Med Genet 1983: 14: 713-724.
15. Mandel JL, Chelly J. Monogenic X-linked mental retardation: is it as frequent as currently estimated? The paradox of the ARX (Aristaless X) mutations. Eur J Hum Genet 2004: 12: 689-693.
16. Yntema HG, Kleefstra T, Oudakker AR et al. Low frequency of MECP2 mutations in mentally retarded males. Eur J Hum Genet 2002: 10: 487-490.
17. Gronskov K, Hjalgrim H, Nielsen IM, Brondum-Nielsen K. Screening of the ARX gene in 682 retarded males. Eur J Hum Genet 2004: 12: 701-705.
18. Bienvenu T, Poirier K, Friocourt G et al. ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. Hum Mol Genet 2002: 11: 981-991.
19. Couvert P, Bienvenu T, Aquaviva C et al. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 2001: 10: 941-946.
20. Rosenberg EH, Almeida LS, Kleefstra T et al. High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am J Hum Genet 2004: 75: 97-105.
21. Wood T, Rosenberg EH, Clark AJ et al. Molecular and biochemical testing of creatine deficiency in an MR population suggests a 1% prevalence. American Society of Human Genetics, 54th annual meeting, Toronto 2004.
22. Kammoun F, de Roux N, Boespflug-Tanguy O et al. Screening of MECP2 coding sequence in patients with phenotypes of decreasing likelihood for Rett syndrome: a cohort of 171 cases. J Med Genet 2004: 41: E85.
23. Maranduba CM, Sa ME, Muller OG et al. Does the P172H mutation at the TM4SF2 gene cause X-linked mental retardation? Am J Med Genet 2004: 124A: 413-415.
24. Billuart P, Bienvenu T, Ronce N et al. Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. Nature 1998: 392: 923-926.
25. Kutsche K, Yntema H, Brandt A et al. Mutations in ARHGEF6, encoding a guanine nucleotide exhange factor for Rho GTPases, in patients with X-linked mental retardation. Nat Genet 2000: 26: 247-250.
26. Allen KM, Gleeson JG, Bagrodia S et al. PAK3 mutation in nonsyndromic X-linked mental retardation. Nat Genet 1998: 20: 25-30.
27. Philip N, Chabrol B, Lossi AM et al. Mutations in the oligophrenin-1 gene (OPHN1) cause X linked congenital cerebellar hypoplasia. J Med Genet 2003: 40: 441-446.
28. Bergmann C, Zerres K, Senderek J et al. Oligophrenin 1 (OPHN1) gene mutation causes syndromic X-linked mental retardation with epilepsy, rostral ventricular enlargement and cerebellar hypoplasia. Brain 2003: 126: 1537-1544.
29. des Portes V, Boddaert N, Sacco S et al. Specific clinical and brain MRI features in mentally retarded patients with mutations in the Oligophrenin-1 gene. Am J Med Genet Part A 2004: 124A: 364-371.
30. Philip N, Chabrol B, Raybaud C et al. Further delineation of the clinical phenotype associated with muttaions in OPHN1 gene: a clinically recognisable syndrome. American Society of Human Genetics, 54th annual meeting, Toronto 2004.
31. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Europ J Paediatr Neurol 2002: 6: 293-297.
32. Mnatzakanian GN, Lohi H, Munteanu I et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 2004: 36: 339-341.
33. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999: 23: 185-188.
34. Villard L, Kpebe A, Cardoso C, Chelly J, Tardieu M, Fontes M. Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 2000: 55: 1188-1193.
35. Wan M, Lee SSJ, Zhang X et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 1999: 65: 1520-1529.
36. Hoffbuhr K, Devaney JM, LaFleur B et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001: 56: 1486-1495.
37. Geerdink N, Rotteveel JJ, Lammens M et al. MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings. Neuropediatrics 2002: 33: 33-36.
38. Zeev BB, Yaron Y, Schanen NC et al. Rett syndrome: clinical manifestations in males with MECP2 mutations. J Child Neurol 2002: 17: 20-24.
39. Leonard H, Silberstein J, Falk R et al. Occurrence of Rett syndrome in boys. J Child Neurol 2001: 16: 333-338.
40. Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. Neuropediatrics 2001: 32: 162-164.
41. Clayton-Smith J, Watson P, Ramsden S, Black GCM. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 2000: 356: 830-832.
42. Armstrong J, Pineda M, Aibar E, Gean E, Monros E. Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation. Ann Neurol 2001: 50: 692.
43. Topcu M, Akyerl C, Sayi A et al. Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. Eur J Hum Genet 2002: 10: 77-81.
44. Kleefstra T, Yntema HG, Nillesen WM et al. MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics. Eur J Hum Genet 2004: 12: 24-28.
45. Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A. A Mutation Hot Spot for Nonspecific X-Linked Mental Retardation in the MECP2 Gene Causes the PPM-X Syndrome. Am J Hum Genet 2002: 70: 1034-1037.
46. Orrico A, Lam CW, Galli L et al. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 2000: 481: 285-288.
47. Meloni I, Bruttini M, Longo I et al. A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 2000: 67: 982-985.
48. Imessaoudene B, Bonnefont JP, Royer G et al. MECP2 mutation in non-fatal, non-progressive encephalopathy in a male. J Med Genet 2001: 38: 171-174.
49. Kleefstra T, Yntema HG, Oudakker AR et al. De novo MECP2 frameshift mutation in a boy with moderate mental retardation, obesity and gynaecomastia. Clin Genet 2002: 61: 359-362.
50. Yntema HG, Oudakker AR, Kleefstra T et al. In frame deletion in MECP2 causes mild nonspecific mental retardation. Am J Med Genet 2002: 107: 81-83.
51. Winnepenninckx B, Errijgers V, Hayez-Delatte F, Reyniers E, Kooy FR. Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: Is there a need for routine screening? Hum Mutat 2002: 20: 249-252.
52. Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist 2004: 10: 118-128.
53. Kudo S, Nomura Y, Segawa M et al. Functional characterisation of MeCP2 mutations found in male patients with X linked mental retardation. J Med Genet 2002: 39: 132-136.
54. Salomons GS, van Dooren SJ, Verhoeven NM et al. X-linked creatine transporter defect: an overview. J Inherit Metab Dis 2003: 26: 309-318.
55. Bizzi A, Bugiani M, Salomons GS et al. X-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8. Ann Neurol 2002: 52: 227-231.
56. Cecil KM, Salomons GS, Ball W et al. Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? Ann Neurol 2001: 49: 401-404.
57. DeGrauw TJ, Salomons GS, Cecil KM et al. Congenital creatine transporter deficiency. Neuropediatrics 2002: 33: 232-238.
58. DeGrauw TJ, Cecil KM, Byars AW, Salomons GS, Ball WS, Jakobs C. The clinical syndrome of creatine transporter deficiency. Mol Cell Biochem 2003: 244: 45-48.
59. Hahn KA, Salomons GS, Tackels-Horne D et al. X-Linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28. Am J Hum Genet 2002: 70: 1349-1356.
60. Mancini GMS, Catsman-Berrevoets CE, De Coo IFM et al. Two novel mutations in SLC6A8 cause creatine transporter defect and X-linked mental retardation in two unrelated dutch families. Am J Med Genet 2005: 132: 288-295.
61. Salomons GS, van Dooren SJ, Verhoeven NM et al. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine- deficiency syndrome. Am J Hum Genet 2001: 68: 1497-1500.
62. Strømme P, Mangelsdorf ME, Shaw MA et al. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet 2002.
63. Stromme P, Mangelsdorf ME, Scheffer IE, Gecz J. Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX. Brain Dev 2002: 24: 266-268.
64. Claes S, Vogels A, Holvoet M, Devriendt K, Raeymaekerr P, Cassiman JJ et al. Regional localization of two genes for nonspecific X-linked mental retardation to Xp22.3-P22 2 (MRX49) Xp11 3-P11 21 (MRX50). Am J Med Genet 1997: 73: 474-479.
65. Bruyere H, Lewis MES, Wood S, MacLeod PJ, Langlois S. Confirmation of linkage in X-linked infantile spasms (West syndrome) refinement disease locus to Xp21 3-Xp22 1. Clin Genet 1999: 55: 173-181.
66. Stromme P, Sundet K, Mork C, Cassiman JJ, Fryns JP, Claes S. X linked mental retardation and infantile spasms in a family: new clinical data and linkage to Xp11.4-X p22.11. J Med Genet 1999: 36: 374-378.
67. Partington MW, Mulley JC, Sutherland GR, Hockey A, Thode A, Turner G. X-linked mental retardation with dystonic movements of the hands. Am J Med Genet 1988: 30: 251-262.
68. Frints SG, Froyen G, Marynen P, Willekens D, Legius E, Fryns JP. Re-evaluation of MRX36 family after discovery of an ARX gene mutation reveals mild neurological features of Partington syndrome. Am J Med Genet 2002: 112: 427-428.
69. Van Esch H, Poirier K, de Zegher F et al. ARX mutation in a boy with transsphenoidal encephalocele and hypopituitarism. Clin Genet 2004: 65: 503-505.
70. Kitamura KO, Yanazawa M, Sugiyama N et al. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat Genet 2002: 32: 359-369.
71. Hahn A, Gross C, Uyanik G et al. X-linked lissencephaly with abnormal genitalia associated with renal phosphate wasting. Neuropediatrics 2004: 35: 202-205.
72. Hartmann H, Uyanik G, Gross C et al. Agenesis of the corpus callosum, abnormal genitalia and intractable epilepsy due to a novel familial mutation in the Aristaless-related homeobox gene. Neuropediatrics 2004: 35: 157-160.
73. Kato M, Das S, Petras K et al. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat 2004: 23: 147-159.
74. Turner G, Partington M, Kerr B, Mangelsdorf M, Gecz J. Variable expression of mental retardation, autism, seizures, and dystonic hand movements in two families with an identical ARX gene mutation. Am J Med Genet 2002: 112: 405-411.
75. Partington MW, Turner G, Boyle J, Gecz J. Three new families with X-linked mental retardation caused by the 428-451dup (24bp) mutation in ARX. Clin Genet 2004: 66: 39-45.
76. Kleefstra T, Yntema HG, Oudakker AR et al. Localization of a gene for nonspecific X-linked mental retardation (MRX 76) to Xp22.3-Xp21.3. Am J Med Genet 2002: 110: 410-411.
77. Hamel BCJ, Smits APT, van den Helm B et al. Four families (MRX43, MRX44, MRX45, MRX52) with non-specific X-linked mental retardation: clinical and psychometric data and results of linkage analysis. Am J Med Genet 1999: 85: 290-304.
78. Colombo E, Galli R, Cossu G, Gecz J, Broccoli V. Mouse orthologue of ARX, a gene mutated in several X-linked forms of mental retardation and epilepsy, is a marker of adult neural stem cells and forebrain GABAergic neurons. Dev Dyn 2004: 231: 631-639.
79. Okazawa H, Sudol M, Rich T. PQBP-1 (Np/PQ): a polyglutamine tract-binding and nuclear inclusion-forming protein. Brain Res Bull 2001: 56: 273-280.
80. Okazawa H, Rich T, Chang A et al. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 2002: 34: 701-713.
81. Waragai M, Lammers CH, Takeuchi S et al. PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Hum Mol Genet 1999: 8: 977-987.
82. Kalscheuer VM, Freude K, Musante L et al. Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation. Nat Genet 2003: 35: 313-115.
83. Lenski C, Abidi F, Meindl A et al. Novel truncating mutations in the polyglutamine tract binding protein 1 gene (PQBP1) cause Renpenning syndrome and X-linked mental retardation in another family with microcephaly. Am J Hum Genet 2004: 74: 777-780.
84. Sutherland GR, Gedeon AK, Haan EA, Woodroffe P, Mulley JC. Linkage studies with the gene for an X-linked syndrome of mental retardation, microcephaly and spastic diplegia (MRX2). Am J Med Genet 1988: 30: 493-508.
85. Kleefstra T, Franken CE, Arens YH et al. Genotype-phenotype studies in three families with mutations in the polyglutamine-binding protein 1 gene (PQBP1). Clin Genet 2004: 66: 318-326.
86. Hamel BCJ, Mariman ECM, van Beersum SEC, Schoonbrood-Lenssen AMJ, Ropers HH. Mental retardation, congenital heart defect, cleft palate, short stature, and facial anomalies: a new X-linked multiple congenital anomalies/mental retardation syndrome: clinical description and molecular studies. Am J Med Genet 1994: 51: 591-597.
87. Renpenning H, Gerrard JW, Zaleski WA, Tabata T. Familial sex-linked mental retardation. Can Med Assoc J 1962: 87: 954-956.
88. Stevenson RE, Bennett CW, Abidi F et al. Renpenning syndrome comes into focus. Am J Med Genet 2005 (in press).
89. Porteous ME, Burn J. Unknown syndrome. A possible new-linked retardation syndrome: dysmorphic facies, microcephaly, hypotonia, and small genitalia. J Med Genet 1990: 27: 339-340.
90. Golabi M, Ito M, Hall BD. A new X-linked multiple congenital anomalies/mental retardation syndrome. Am J Med Genet 1984: 17: 367-374.
91. Deqaqi SC, N'Guessan M, Forner J et al. Gene for non-specific X-linked mental retardation (MRX55) is located in Xp11. Ann Genet 1998: 41: 11-16.
92. Jensen LR, Amende M, Gurok U et al. Mutations in the JARID1C Gene, Which Is Involved in Transcriptional Regulation and Chromatin Remodeling, Cause X-Linked Mental Retardation. Am J Hum Genet 2004: 76: 227-236.
93. Agulnik AI, Mitchell MJ, Mattei MG et al. A novel X gene with a widely transcribed Y-linked homologue escapes X-inactivation in mouse and human. Hum Mol Genet 1994: 3: 879-884.
94. Clissold PM, Ponting CP. JmjC: cupin metalloenzyme-like domains in jumonji, hairless and phospholipase A2beta. Trends Biochem Sci 2001: 26: 7-9.
95. Chiurazzi P, Neri G, Oostra BA. Understanding the biological underpinnings of fragile X syndrome. Curr Opin Pediatr 2003: 15: 559-566.
96. Kooy RF. of mice and the fragile X syndrome. Trends Genet 2003: 19: 148-154.
97. Willemsen R, Oostra BA, Bassell GJ, Dictenberg J. The fragile X syndrome: from molecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev 2004: 10: 60-67.
98. Yntema HG. Molecular Genetics of Nonspecific X-linked Mental Retardation. PhD Thesis. Nijmegen (webdoc.ubn.kun.nl/mono/i/ijntema_h/molegeofn.pdf) 2001
99. Ramakers GJA. Rho proteins and the cellular mechanisms of mental retardation. Am J Med Genet 2000: 94: 367-371.
100. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003: 278: 4035-4040.
101. Cardoso C, Timsit S, Villard L, Khrestchatisky M, Fontes M, Colleaux L. Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. Hum Mol Genet 1998: 7: 679-684.
102. Ayyanathan K, Lechner MS, Bell P et al. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev 2003: 17: 1855-1869.
103. Merienne K, Pannetier S, Harel-Bellan A, Sassone-Corsi P. Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities. Mol Cell Biol 2001: 21: 7089-7096.
104. Laumonnier F, Bonnet-Brilhault F, Gomot M et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004: 74: 552-557.
105. Tarpey P, Parnau J, Blow M et al. Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet 2004: 75: 318-324.
106. Jamain S, Quach H, Betancur C et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003: 34: 27-29.
107. Bächner D, Sedlacek Z, Korn B, Hameister H, Poustka A. Expression patterns of two human genes coding for different rab GDP- dissociation inhibitors (GDIs), extremely conserved proteins involved in cellular transport. Hum Mol Genet 1995: 4: 701-708.
108. Sasaki T, Kikuchi A, Araki S et al. Purification and characterization from bovine brain cytosol of a protein that inhibits the dissociation of GDP from and the subsequent binding of GTP to smg p25A, a ras p21-like GTP-binding protein. J Biol Chem 1990: 265: 2333-2337.
109. Bahi N, Friocourt G, Carrie A et al. IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. Hum Mol Genet 2003: 12: 1415-1425.
110. Meloni I, Muscoletta M, Raynaud M et al. FACL4, encoding fatty acid-CoA ligase 4, is mutated in non-specific X-linked mental retardation. Nat Genet 2002: 30: 436-440.
111. Freude K, Hoffmann K, Jensen LR et al. Mutations in the FTSJ1 gene coding for a novel S-adenosylmethionine-binding protein cause nonsyndromic X-linked mental retardation. Am J Hum Genet 2004: 75: 305-309.
112. Chelly J, Mandel JL. Monogenic causes of X-linked mental retardation. Nat Rev Genet 2001: 2: 669-680.
113. Mandel JL. Comparative frequency of fragile-X (FMR1) and creative transporter (SLC6A8) mutations in X-linked mental retardation. Am J Hum Genet 2004: 75: 730-731.
114. Zechner U, Wilda M, Kehrer-Sawatzki H, Vogel W, Fundele R, Hameister H. A high density of X-linked genes for general cognitive ability: a run-away process shaping human evolution? Trends Genet 2001: 17: 697-701.
115. Turner G. Intelligence and the X chromosome. Lancet 1996: 347: 1814-1815.
116. Lubs HA. The other side of the coin. a hypothesis concerning the importance of genes for high intelligence and evolution of the X chromosome. Am J Med Genet 1999: 85: 206-208.
117. Richards BW, Sylvester PE, Brooker C. Fragile X-linked mental retardation: the Martin-Bell syndrome. J Ment Defic Res 1981: 25 Pt 4: 253-256.
118. Adams MD, Kerlavage AR, Fleischmann RD et al. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature 1995: 377 (Suppl.): 3-17.
119. Bond J, Roberts E, Mochida GH, Hampshire DJ et al. ASPM is a major determinant of cerebral cortical size. Nat Genet 2002: 32: 316-320.
120. Jackson AP, Eastwood H, Bell SM et al. Identification of microcephalin, a protein implicated in determining the size of the human brain. Am J Hum Genet 2002: 71: 136-142.
121. Molinari F, Rio M, Meskenaite V et al. Truncating neurotrypsin mutation in autosomal recessive nonsyndromic mental retardation. Science 2002: 298: 1779-1781.
122. Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP. Candidate genes for recessive non-syndromic mental retardation on chromosome 3p (MRT2A). Clin Genet 2004: 65: 496-500.
123. Basel-Vanagaite L, Alkelai A, Straussberg R et al. Mapping of a new locus for autosomal recessive non-syndromic mental retardation in the chromosomal region 19p13.12-p13.2: further genetic heterogeneity. J Med Genet 2003: 40: 729-732.
124. Koolen DA, Nillesen WM, Versteeg MH et al. Screening for subtelomeric rearrangements in 210 patients with unexplained mental retardation using multiplex ligation dependent probe amplification (MLPA). J Med Genet 2004: 41: 892-899.
125. Vissers LE, de Vries BB, Osoegawa K et al. Array-Based Comparative Genomic Hybridization for the Genomewide Detection of Submicroscopic Chromosomal Abnormalities. Am J Hum Genet 2003: 73: 1261-1270.
126. Vissers LE, van Ravenswaaij CM, Admiraal R et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004: 36: 955-957.
127. Bi W, Saifi GM, Shaw C et al. Mutations of RAI1, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome. Hum Genet 2004: 115: 515-524.
128. Petrij F, Giles RH, Dauwerse HG et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co- activator CBP. Nature 1995: 376: 348-351.
129. Matsuura T, Sutcliffe JS, Fang P et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997: 15: 74-77.
130. Kleefstra T, Smidt M, Banning JG et al. Disruption of the gene Euchromatin Histone Methyl Transferase 1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome. J Med Genet 2005: in press.
131. Bonaglia MC, Giorda R, Borgatti R et al. Disruption of the ProSAP2 gene in a (12; 22)(q24.1; q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 2001: 69: 261-268.
132. Fernandez T, Morgan T, Davis N et al. Disruption of Contactin 4 (CNTN4) Results in Developmental Delay and Other Features of 3p Deletion Syndrome. Am J Hum Genet 2004: 74: 1286-1293.
133. Frints SG, Marynen P, Hartmann D et al. CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Mol Genet 2003: 12: 1463-1474.
134. Winnick E. DNA sequencing industry sets its sights on the future. The Scientist 2004: 18: 44-47.
135. Pe'er I, Arbili N, Liu Y, Enck C, Gelfand CA, Shamir R. Advanced computational techniques for re-sequencing DNA with polymerase signaling assay arrays. Nucleic Acids Res 2003: 31: 5667-5675.